Dr. Reddy’s is recalling five lots of Javygtor and one lot of generic sapropterin dihydrochloride because discoloration could lead to decreased potency. Sapropterin is used to treat an inherited metabolic disorder.
Dr. Reddy's Laboratories is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg due to powder discoloration in some packets. This could lead to decreased potency. The issue was discovered because of customer complaints and from accelerated stability test.
Sapropterin Dihydrochloride is used to treat adult and pediatric patients one month of age and older with the metabolic disorder hyperphenylalaninemia (HPA) that is the result of tetrahydrobiopterin-responsive Phenylketonuria (PKU). It is indicated to reduce the level of phenylalanine (Phe) in the blood.
Hyperphenylalaninemia is an abnormal increase in the amino acid phenylalanine in the blood. High concentrations of phenylalanine can lead to Phenylketonuria, a condition where there is decreased activity of a liver enzyme called phenylalanine hydroxylase. Untreated, the condition can lead to microcephaly, delayed or absent speech, seizures, eczema, and behavioral issues.
Lowered potency of Sapropterin Dihydrochloride could result in elevated phenylalaninemia levels in patients. Chronically elevated Phe levels in infants and children can cause permanent neurologic deficits.
The recall affects five lots of the branded product Javygtor and one lot of the generic product sapropterin. The products are packaged in individual packets with 30 per carton. NDC and lot numbers of the affected products can be found here.
Javygtor was developed by Cycle Pharmaceuticals, which partnered with Dr. Reddy’s for distribution. Javygtor was launched in October 2022.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More